Research programme - antibody-drug conjugates - Innate Pharma/Sanofi

Drug Profile

Research programme - antibody-drug conjugates - Innate Pharma/Sanofi

Alternative Names: Anticancer therapeutics - Innate Pharma/Sanofi

Latest Information Update: 12 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innate Pharma; Sanofi
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Natural cytotoxicity triggering receptor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 09 Feb 2016 Sanofi and Innate Pharma enter into a research and licensing agreement utlising Innate Pharma’s proprietary technology to develop bispecific antibody conjugates for Cancer
  • 16 Apr 2015 Innate Pharma and Sanofi enter into collaboration to develop antibody-drug conjugates for Cancer
  • 16 Apr 2015 Early research in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top